Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

DOI: 10.1016/s0140-6736(17)32440-6
Lancet, The, 2017, 390, 1949-1961.

#	Paper	IF	Citations
1071	Malignant external otitis. **1987**, 101, 205-10		51
1070	Targeted therapy: ARIEL3 - broad benefit of PARP inhibitors in ovarian cancer. **2017**, 14, 713		2
1069	PARP inhibitors: Clinical utility and possibilities of overcoming resistance. **2017**, 147, 695-704		131
1068	PARP inhibitors for targeted treatment in ovarian cancer. *Lancet, The*, **2017**, 390, 1929-1930	40	18
1067	Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer. **2017**, 23, 1121-1137		28
1066	Emerging treatment options for ovarian cancer: focus on rucaparib. **2017**, 9, 913-924		16
1065	PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. **2017**, 4, 18		31
1064	PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. **2018**, 81, 647-658		47
1063	Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. **2018**, 20, 18		4
1062	Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions. **2018**, 40, 361-371		29
1061	Rucaparib: a new treatment option for ovarian cancer. **2018**, 19, 765-771		5
1060	Update on PARP Inhibitors in Breast Cancer. **2018**, 19, 21		55
1059	PARP inhibitors and breast cancer: highlights and hang-ups. **2018**, 3, 83-94		3
1058	The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. **2018**, 149, 214-220		34
1057	Management of the toxicities of common targeted therapeutics for gynecologic cancers. **2018**, 148, 591-600		21
1056	Rucaparib for the treatment of ovarian cancer. **2018**, 6, 151-161		
1055	Targeting DNA repair: the genome as a potential biomarker. **2018**, 244, 586-597		28

1054	The Chemoprevention of Ovarian Cancer: the Need and the Options. **2018**, 4, 250-260	8
1053	Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. **2018**, 66, 7-14	40
1052	PARP inhibitors for homologous recombination-deficient prostate cancer. **2018**, 23, 123-133	18
1051	The Current Landscape of PARP Inhibitors in Ovarian Cancer. **2018**, 7, 20-27	2
1050	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. **2018**, 118, 938-946	19
1049	Location of Mutation in Gene and Survival in Patients with Ovarian Cancer. **2018**, 24, 326-333	28
1048	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. **2018**, 36, 1020-1044	83
1047	Moving From Mutation to Actionability. **2018**, 38, 495-503	4
1046	Inherited gynaecological cancers. **2018**, 30, 317-322	
1045	Reversal of Bowel Obstruction With Platinum-Based Chemotherapy and Olaparib in Recurrent, Short Platinum-Free Interval, RAD51C Germline Mutation-Associated Ovarian Cancer.. **2018**, 2, 1-8	2
1044	Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer. **2018**, 26, 91-93	3
1043	Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. **2018**, 25, 2617-2633	49
1042	How safe is rucaparib in ovarian cancer?. **2018**, 17, 1249-1255	1
1041	Targeted treatment of advanced ovarian cancer: spotlight on rucaparib. **2018**, 14, 2189-2201	8
1040	Non-Coding Variants in and Genes: Potential Impact on Breast and Ovarian Cancer Predisposition. **2018**, 10,	9
1039	Management and Treatment of Recurrent Epithelial Ovarian Cancer. **2018**, 32, 965-982	28
1038	Population Based Testing for Primary Prevention: A Systematic Review. **2018**, 10,	23
1037	Recent Advances in Homogeneous Metal-Catalyzed Aerobic C–H Oxidation of Benzylic Compounds. **2018**, 8, 640	15

1036	Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. **2018**, 10,	102
1035	PARP Inhibitors in Ovarian Cancer. **2018**, 13, 392-410	60
1034	Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. **2018**, 19, 1	29
1033	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. **2018**, 9, 3970	111
1032	Defective DNA repair in hereditary ovarian cancers: Implications for therapy. **2018**, 75, 1697-1707	4
1031	RNA interference to enhance radiation therapy: Targeting the DNA damage response. **2018**, 439, 14-23	7
1030	Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. **2018**, 12, 3013-3019	14
1029	Cancer of the ovary, fallopian tube, and peritoneum. **2018**, 143 Suppl 2, 59-78	116
1028	Targeted therapy for gynecologic cancers: Toward the era of precision medicine. **2018**, 143 Suppl 2, 131-136	13
1027	A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. **2018**, 10,	85
1026	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. **2018**, 119, 1401-1409	100
1025	Low-grade Serous Ovarian Carcinoma. **2018**, 78, 972-976	15
1024	Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. **2018**, 73, e450s	45
1023	Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy. **2018**, 109, 3383-3392	21
1022	Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. **2018**, 19,	2
1021	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. **2018**, 379, 2495-2505	1061
1020	Major clinical research advances in gynecologic cancer in 2017. **2018**, 29, e31	18
1019	The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis. **2018**, 131, 83-89	29

1018	Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin´+´pegylated liposomal doxorubicin in second line. **2018**, 18, 13-17	1
1017	Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. **2018**, 71, 1-7	56
1016	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. **2018**, 19, 1360-1371	38
1015	Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial. **2018**, 151, 39-45	15
1014	Safety and dose modification for patients receiving niraparib. **2018**, 29, 1784-1792	78
1013	Challenges with biomarkers in cancer drug discovery and development. **2018**, 13, 685-690	20
1012	Biomarkers for Homologous Recombination Deficiency in Cancer. **2018**, 110, 704-713	122
1011	A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients. **2018**, 24, 4482-4493	46
1010	The role of niraparib for the treatment of ovarian cancer. **2018**, 14, 2565-2577	6
1009	Financial toxicity - An overlooked side effect. **2018**, 150, 3-6	11
1008	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. **2018**, 30, 515-524	10
1007	Metastatic gynecologic malignancies: advances in treatment and management. **2018**, 35, 521-533	6
1006	PARP Inhibitors in Epithelial Ovarian Cancer. **2018**, 13, 145-158	31
1005	Inherent and toxicant-provoked reduction in DNA repair capacity: A key mechanism for personalized risk assessment, cancer prevention and intervention, and response to therapy. **2018**, 221, 993-1006	7
1004	Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. **2018**, 10, 1758835918778483	15
1003	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. **2018**, 19, 1117-1125	65
1002	Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. **2018**, 10, 1758835918786658	73
1001	Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. **2018**, 29, 1366-1376	76

1000	Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. **2018**, 12, 1501-1509	24
999	Rucaparib: a novel PARP inhibitor for advanced ovarian cancer. **2018**, 12, 605-617	16
998	Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation. **2018**, 18, 947-958	4
997	Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. **2018**, 5,	80
996	Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways. **2018**, 6, 161	3
995	Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. **2018**, 14, 3101-3110	6
994	Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. **2018**, 151, 46-52	29
993	PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey. **2018**, 24, 4062-4065	25
992	Emerging therapeutic modalities of PARP inhibitors in breast cancer. **2018**, 68, 62-68	24
991	Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?. **2018**, 69, 53-65	22
990	Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?. **2018**, 20, 63	2
989	Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors. **2019**, 8, 107-118	16
988	Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?. **2019**, 36, 72-75	2
987	Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. **2019**, 8,	24
986	Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer. **2019**, 37, 2424-2436	16
985	Immunotherapy in Ovarian Cancer: Are We There Yet?. **2019**, 37, 2460-2471	43
984	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. **2019**, 20, 1306-1315	52
983	A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. **2019**, 84, 791-798	11

982	Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. **2019**, 12, 1386-1394	5
981	Evidence to date: talazoparib in the treatment of breast cancer. **2019**, 12, 5177-5187	22
980	Overcoming Resistance to PARP Inhibition. **2019**, 161-189	
979	Current Applications for Overcoming Resistance to Targeted Therapies. **2019**,	1
978	Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. **2019**,	4
977	Fallopian Tube Carcinoma. **2019**, 15, 375-382	13
976	The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report. **2019**, 30, e91	5
975	The Evolving Arena of Ovarian Cancer Maintenance Therapy. **2019**, 97, 202-205	2
974	PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy. **2019**, 49, 703-707	12
973	BRCA germline mutation test for all woman with ovarian cancer?. **2019**, 19, 641	6
972	Pharmaceutical Management of Ovarian Cancer: Current Status. **2019**, 79, 1231-1239	19
971	Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. **2019**, 80, 101909	43
970	Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. **2019**, 155, 262-269	11
969	Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study. **2019**, 155, 400-405	12
968	PARP Inhibition in Cancer: An Update on Clinical Development. **2019**, 14, 657-679	91
967	Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis. **2019**, 36, 3368-3380	10
966	Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. **2019**, 5, 1731-1738	79
965	BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients. **2019**, 215, 152595	1

964	Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review. **2019**, 12, 103	34
963	Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study. **2019**, 15, 4197-4206	6
962	Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. **2019**, 381, 1929-1939	127
961	Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility. **2019**, 155, 473-482	3
960	A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients. **2019**, 11, 8869-8876	2
959	Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints. **2019**, 28, 771-785	8
958	Olaparib maintenance for first-line treatment of ovarian cancer:´will SOLO1 reset the standard of care?. **2019**, 15, 1845-1853	10
957	Olaparib in the treatment of ovarian cancer. **2019**, 15, 3435-3449	9
956	Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. **2019**, 20, 1409-1419	105
955	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. **2019**, 11,	8
954	Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. **2019**, 14, 505-525	20
953	Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. **2019**, 16, 725-726	13
952	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. **2019**, 381, 2403-2415	334
951	Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. **2019**, 19, 901	20
950	Prevalence of germline pathogenic variants in sequential epithelial ovarian cancer cases. **2019**, 56, 301-307	12
949	Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. **2019**, 12, 9	45
948	Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas. **2019**, 145, 1209-1220	15
947	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. **2019**, 5, 393-401	178

946	PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. **2019**, 23, 2303-2313	57
945	Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil. **2019**, 19, 4	8
944	Secondary hematologic malignancies with poly adenosine diphosphate ribose polymerase inhibitors: Is the buzz real? -Insights from a meta-analysis of phase 3 randomized controlled trials. **2019**, 10, 518-520	2
943	Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management. **2019**, 46, 67-88	8
942	Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care. **2019**, 46, 137-154	3
941	PET Imaging of PARP Expression Using F-Olaparib. **2019**, 60, 502-503	2
940	Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. **2019**, 11, 1758835919849753	49
939	Functional Loss Defines a Targetable Subset in Leiomyosarcoma. **2019**, 24, 973-979	23
938	Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers. **2019**, 7, 116-123	
937	The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers. **2019**, 178, 81-108	2
936	A decade of clinical development of PARP inhibitors in perspective. **2019**, 30, 1437-1447	218
935	Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. **2019**, 4, e000480	31
934	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. **2019**, 10, 3533-3546	12
933	Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. **2019**, 11,	12
932	Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. **2019**, 37, 2968-2973	54
931	Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". **2019**, 37, 1065-1067	4
930	A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. **2019**, 154, 294-301	44
929	Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look". **2019**, 154, 290-293	2

928	Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy. **2019**, 19, 589-601	5
927	Newer biological agents: CAR T cells, PARP inhibitors, and ALK inhibitors. **2019**, 3, 92-97	
926	PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca". **2019**, 9,	35
925	The current state of molecular testing in the treatment of patients with solid tumors, 2019. **2019**, 69, 305-343	86
924	Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. **2019**, 201, 94-102	63
923	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. **2019**, 154, 144-149	16
922	Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes. **2019** , 19, 422	11
921	Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. **2019**, 12, 40	28
920	Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies. **2019**, 14, 269-283	6
919	The DNA Damaging Revolution: PARP Inhibitors and Beyond. **2019**, 39, 185-195	81
918	Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. **2019**, 39, e152-e166	8
917	Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. **2019**, 11, 4371-4390	57
916	Veliparib: a new therapeutic option in ovarian cancer?. **2019**, 15, 1975-1987	5
915	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. **2019**, 3,	29
914	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. **2019**, 69, 280-304	292
913	Next-generation sequencing of and genes for rapid detection of germline mutations in hereditary breast/ovarian cancer. **2019**, 7, e6661	10
912	ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease **2019**, 30, 672-705	298
911	ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. **2019**,	71

910	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. **2019**, 37, 2257-2269		69
909	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. **2019**, 167, 133-148		14
908	Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. **2019**, 30, 721-732		24
907	Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice. **2019**, 24, 576-579		
906	Identifying disparities in germline and somatic testing for ovarian cancer. **2019**, 153, 297-303		12
905	DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors. **2019**, 35, 519-533.e8		49
904	PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review. **2019**, 33, 255-273		25
903	Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics. **2019**, 13, 904		7
902	Poly (ADP-Ribose) Polymerase Inhibition for Chemotherapy-Induced Peripheral Neuropathy: A Meta-Analysis of Placebo-Controlled Trials. **2019**, 22, 977-980		3
901	High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. **2019**, 20,		156
900	Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study. **2019**, 299, 1641-1649		3
899	Rucaparib: A Review in Ovarian Cancer. **2019**, 14, 237-246		14
898	Epithelial ovarian cancer. *Lancet, The*, **2019**, 393, 1240-1253	40	463
897	Tailoring Ovarian Cancer Treatment: Implications of Mutations. **2019**, 11,		34
896	Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. **2019**, 152, 445-451		2
895	New and Novel Therapies for Gynecologic Cancers. **2019**, 35, 217-219		6
894	Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types. **2019**, 11,		8
893	Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy. **2019**, 8, 577-587		3

892	Subcellular compartmentalization of NAD and its role in cancer: A sereNADe of metabolic melodies. **2019**, 200, 27-41	30
891	Rucaparib in the landscape of PARP inhibition in ovarian cancer. **2019**, 19, 437-446	1
890	Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. **2019**, 25, 5441-5448	149
889	Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?. **2019**, 20, 603-605	2
888	Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. **2019**, 20, 1035-1045	12
887	PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. **2019**, 8,	65
886	Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. **2019**, 454, 171-178	6
885	Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. **2019**, 110, 1064-1075	27
884	PARP Inhibitors: Extending Benefit Beyond -Mutant Cancers. **2019**, 25, 3759-3771	141
883	Asian Society of Gynecologic Oncology International Workshop 2018. **2019**, 30, e39	6
882	Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors. **2019**, 4, 11-25	1
881	Phase III trials in ovarian cancer: The evolving landscape of front line therapy. **2019**, 153, 436-444	13
880	Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. **2019**, 9, 1853	98
879	Chemotherapy Toxicity in Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy. **2019**, 24, e1471-e1475	5
878	Treatment of recurrent epithelial ovarian cancer. **2019**, 125 Suppl 24, 4609-4615	27
877	Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date. **2019**, 12, 11497-11506	6
876	Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?. **2019**, 7, S372	5
875	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. **2019**, 24, 1340-1347	43

874	MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers. **2019**, 116, 17438-17443	16
873	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, -mutated, high-grade ovarian cancer, and an update on safety. **2019**, 29, 1396-1404	11
872	Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review. **2019**, 05, 01-18	
871	Personalized Medicine in Oncology Drug Development. **2019**, 1-11	
870	Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. **2019**, 12,	13
869	Advances and perspectives of PARP inhibitors. **2019**, 8, 29	52
868	Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline mutations: OPINION Phase IIIb study design. **2019**, 15, 3651-3663	4
867	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. **2019**, 9, 1289	6
866	Emerging serine-threonine kinase inhibitors for treating ovarian cancer. **2019**, 24, 239-253	3
865	Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients. **2019**, 9, 17808	18
864	Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. **2019**, 16,	11
863	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. **2019**, 381, 2416-2428	509
862	Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. **2019**, 11,	23
861	A Comprehensive Review of Ovarian Serous Carcinoma. **2019**, 26, 329-339	18
860	Maintenance Therapy in Metastatic Solid Tumors: Innovative Strategy or Simple Second-line Treatment?. **2019**, 42, 615-623	1
859	Biomarkers in ovarian cancer: To be or not to be. **2019**, 125 Suppl 24, 4563-4572	16
858	Practical Cancer Genetics and Genomics in Women's Health. **2019**, 62, 687-699	1
857	Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?. **2019**, 31, 394-403	2

856	U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. **2019**, 133, 795-802	14
855	Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy. **2019**, 125 Suppl 24, 4582-4586	16
854	Exploring and comparing adverse events between PARP inhibitors. **2019**, 20, e15-e28	138
853	Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research. **2019**, 31, 4-11	7
852	Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States. **2019**, 37, 391-405	20
851	Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review. **2019**, 152, 416-425	24
850	PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers. **2019**, 3, 131-150	36
849	Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review. **2019**, 1863, 371-378	27
848	Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. **2019**, 9, 210-219	142
847	Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor. **2019**, 12, 58-65	9
846	Exaggeration of PFS by blinded, independent, central review (BICR). **2019**, 30, 332-338	8
845	High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature. **2019**, 14, 4	5
844	Epigenetic therapy for ovarian cancer: promise and progress. **2019**, 11, 7	91
843	Medikamentöse Therapie des Ovarialkarzinoms in der Primär- und Rezidivsituation. **2019**, 25, 131-144	
842	State-of-the-art strategies for targeting the DNA damage response in cancer. **2019**, 16, 81-104	412
841	Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. **2019**, 133, 58-73	20
840	International Gynecologic Cancer Society (IGCS) 2018: Meeting report. **2019**, 152, 7-10	2
839	PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. **2019**, 10, 337-345	11

838	Predictive Biomarkers and Targeted Therapies in Gynecological Cancers. **2019**, 445-456	
837	Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. **2019**, 152, 270-277	8
836	PARP inhibitors in ovarian cancer. **2019**, 73, 1-9	110
835	Epithelial ovarian cancer risk: A review of the current genetic landscape. **2020**, 97, 54-63	18
834	Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition. **2020**, 112, 161-169	25
833	A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer. **2020**, 38, 392-401	4
832	Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis. **2020**, 73, 168-171	7
831	Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. **2020**, 25, e109-e119	7
830	Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. **2020**, 9, 1296-1306	2
829	Genetic testing in ovarian cancer - clinical impact and current practices. **2019**, 41,	3
828	Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer. **2020**, 45, 828-841	2
827	Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. **2020**, 146, 439-448	19
826	Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. **2020**, 156, 38-44	27
825	Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy. **2020**, 146, 1851-1861	3
824	PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. **2020**, 26, 718-729	5
823	Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making. **2020**, 156, 517-522	8
822	Maintenance Therapy in the Treatment of Recurrent Epithelial Ovarian Cancer. **2020**, 63, 86-91	
821	Targeted therapies in gynaecological cancers. **2020**, 76, 157-170	22

820	A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. **2020**, 156, 13-22	4
819	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. **2020**, 13, 410-422	25
818	Latest clinical evidence of maintenance therapy in ovarian cancer. **2020**, 32, 15-21	13
817	A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. **2020**, 156, 23-31	20
816	Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. **2020**, 122, 483-490	6
815	Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?. **2020**, 207, 107450	54
814	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. **2020**, 26, 1372-1384	38
813	Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening. **2020**, 31, 101-109	3
812	Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients. **2020**, 41, 696-708	9
811	Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors. **2020**, 522, 121-126	10
810	Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. **2020**, 146, 721-737	12
809	Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. **2020**, 156, 415-422	13
808	Maintenance Therapy in the Primary Treatment of Epithelial Ovarian Cancer. **2020**, 63, 80-85	
807	Clinical assays for assessment of homologous recombination DNA repair deficiency. **2020**, 159, 887-898	21
806	Newly diagnosed ovarian cancer: Which first-line treatment?. **2020**, 91, 102111	10
805	Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer. **2020**, 159, 581-587	1
804	Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). **2020**, 30, 1657-1664	63
803	Survival benefits of PARP inhibitors in advanced breast cancer: a´mirage?. **2020**, 31, 1432-1434	1

802	Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. **2020**, 261, 118434	6
801	The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib. **2020**, 159, 850-859	1
800	Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis. **2020**, 12,	7
799	Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin. **2020**, 34, 100652	5
798	The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. **2020**, 17, 1002-1013	6
797	High-throughput approaches for precision medicine in high-grade serous ovarian cancer. **2020**, 13, 134	12
796	ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. **2020**, 31, 1606-1622	62
795	Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?. **2020**, 61, 103046	2
794	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. **2020**, 139, 59-67	3
793	Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. **2020**, 25, 445-453	7
792	The DNA damaging revolution. **2020**, 156, 103117	6
791	Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. **2020**, 159, 483-490	8
790	Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review. **2020**, 26, 1977-1986	2
789	Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. **2020**, 28, 1541-1547	11
788	Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. **2020**, 2020, 6423936	1
787	Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma. **2020**, 21,	17
786	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. **2020**, 31, 1135-1147	27
785	Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer. **2020**, 146, 2559-2574	1

784	Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy. **2020**, 18, 439	4
783	Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort. **2020**, 10, 20223	7
782	DNA damaging agents in ovarian cancer. **2020**, 15, 67-72	1
781	Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements. **2020**, 12,	2
780	Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. **2020**, 21, 1661-1672	26
779	Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers. **2021**, 77, 110-126	9
778	Measuring Quality of Life in Ovarian Cancer Clinical Trials-Can We Improve Objectivity and Cross Trial Comparisons?. **2020**, 12,	3
777	Improved prognosis for recurrent epithelial ovarian cancer by early diagnosis and 125I seeds implantation during suboptimal secondary cytoreductive surgery: a case report and literature review. **2020**, 13, 141	2
776	Treatment of epithelial ovarian cancer. **2020**, 371, m3773	88
775	Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement. **2020**, 159, 8-12	7
774	Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. **2020**, 12,	9
773	The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction. **2020**, 203, 112570	14
772	Rucaparib antagonize multidrug resistance in cervical cancer cells through blocking the function of ABC transporters. **2020**, 759, 145000	5
771	PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives. **2020**, 12, 6123-6135	9
770	Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. **2020**, 5, 137	33
769	Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience. **2020**, 10, 1095	1
768	Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer. **2020**, 20, 703	8
767	Tumor Testing for Somatic and Germline / Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects. **2020**, 10, 1318	3

766	Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. **2020**, 30, 1303-1307	12
765	PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials. **2020**, 10, 1204	3
764	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. **2020**, 159, 79-87	4
763	PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. **2020**, 12, 1758835920944116	12
762	PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. **2020**, 38, 3468-3493	60
761	A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. **2020**, 26, 5462-5476	14
760	Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. **2020**, 90, 102107	8
759	Recycling the Purpose of Old Drugs to Treat Ovarian Cancer. **2020**, 21,	5
758	Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice. **2020**, 159, 112-117	2
757	[Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications]. **2020**, 40, 70-77	1
756	Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene. **2020**, 24, 11177-11187	11
755	Poly(ADP-ribose) polymerase inhibition: past, present and future. **2020**, 19, 711-736	81
754	Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. **2020**, 13, 118	31
753	Secondary and tertiary ovarian cancer recurrence: what is the best management?. **2020**, 9, 1118-1129	3
752	Development of new medical treatment for epithelial ovarian cancer recurrence. **2020**, 9, 1149-1163	3
751	The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. **2020**, 30, 1608-1618	1
750	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. **2020**, 38, 3494-3505	13
749	PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies. **2020**, 9, 51	2

748	Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?. **2020**, 32, 442-450	4
747	Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives. **2020**, 12,	6
746	Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?. **2020**, 302, 1087-1102	14
745	Using sulfuramidimidoyl fluorides that undergo sulfur(VI) fluoride exchange for inverse drug discovery. **2020**, 12, 906-913	27
744	BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. **2020**, 60, 102988	11
743	Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling. **2020**, 8, 109-119	
742	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. **2020**, 30, 1569-1575	5
741	Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis. **2020**, 30, 1576-1582	4
740	PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. **2020**, 8, 564601	100
739	Prevalence of and Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?. **2020**, 80, 932-940	4
738	Breast cancer (BRCA) gene testing in ovarian cancer. **2020**, 9, 63	1
737	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. **2020**, 159, 101-111	7
736	Genomic Strategies for Personalized Cancer Therapy. **2020**, 1-60	
735	Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery. **2020**, 13, 91	0
734	When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. **2020**, 3, 594-611	26
733	Molecular Features and Clinical Management of Hereditary Gynecological Cancers. **2020**, 21,	4
732	Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment. **2020**, 30, 1603-1607	2
731	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial. **2020**, 1, 100068	3

730	Treatment of Recurrent Epithelial Ovarian Cancer. **2020**, 80, 1195-1204	5
729	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. **2020**, 4,	6
728	Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. **2020**, 30, 1026-1033	2
727	PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair. **2020**, 40, 1-16	10
726	Therapeutic applications of PARP inhibitors in ovarian cancer. **2020**, 127, 110204	15
725	Pan-Cancer Analysis of and Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. **2020**, 4, 442-465	38
724	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. **2020**, 26, 4268-4279	59
723	Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. **2020**, 182, 491-502	1
722	Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. **2020**, 12,	4
721	Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. **2020**, 158, 16-24	29
720	Immune Therapy Opportunities in Ovarian Cancer. **2020**, 40, 1-13	10
719	Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials. **2020**, 60, 1334-1343	3
718	Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. **2020**, 87, 102040	18
717	Biomarker-Guided Development of DNA Repair Inhibitors. **2020**, 78, 1070-1085	67
716	PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?. **2020**, 12,	15
715	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. **2020**, 21,	12
714	Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. **2020**, 8,	6
713	Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. **2020**, 12,	7

712	in Breast and Ovarian Cancers. **2020**, 21,	7
711	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. **2020**, 12,	55
710	Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells. **2020**, 12,	5
709	Old dogs, new trick: classic cancer therapies activate cGAS. **2020**, 30, 639-648	37
708	The prognostic value of ITGA and ITGB superfamily members in patients with high grade serous ovarian cancer. **2020**, 20, 257	8
707	PARP inhibitor resistance: the underlying mechanisms and clinical implications. **2020**, 19, 107	73
706	Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors. **2020**, 25, 165-188	6
705	ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738. **2020**, 1, 197-205	7
704	Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance. **2020**, 15, 391-406	4
703	Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. **2020**, 12, 1758835920921980	1
702	SOLO 3 Trial: How Do the Results Fit in With Current Evidence?. **2020**, 38, 2697-2698	1
701	The forefront of ovarian cancer therapy: update on PARP inhibitors. **2020**, 31, 1148-1159	78
700	State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer. **2020**, 21, 1579-1590	3
699	The emerging role of precision medicine in the treatment of ovarian cancer. **2020**, 5, 283-297	3
698	Beyond the Variants: Mutational Patterns in Next-Generation Sequencing Data for Cancer Precision Medicine. **2020**, 8, 370	2
697	Wnt Signaling in Gynecologic Malignancies. **2020**, 21,	19
696	How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors. **2020**, 12, 1758835919897530	3
695	The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. **2020**, 10, 35	35

694	Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. **2020**, 54, 1010-1015	3
693	PARP inhibitors in the treatment of ovarian cancer. **2020**, 13, 198-201	0
692	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. **2020**, 11, 1459	82
691	Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. **2020**, 16, 1363-1375	7
690	Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. **2020**, 30, 684-694	3
689	Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. **2020**, 57, 509-518	14
688	ATM-Deficient Cancers Provide New Opportunities for Precision Oncology. **2020**, 12,	38
687	Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. **2020**, 9,	20
686	Tratamiento quirÍgico de las recidivas de los tumores epiteliales del ovario. **2020**, 56, 1-8	
685	Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer. **2020**, 12,	11
684	Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. **2020**, 20, 204	9
683	The Development of Rucaparib/Rubracafi : A Story of the Synergy Between Science and Serendipity. **2020**, 12,	5
682	Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer. **2020**, 12, e11177	17
681	Evaluation of absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor. **2020**, 50, 1032-1042	11
680	Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. **2020**, 20, 185	7
679	Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer. **2020**, 10, 958	5
678	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. **2020**, 12,	2
677	Homologous recombination deficiency in epithelial ovarian cancer. **2020**, 13, 367-370	0

676	Pharmacological methods to transcriptionally modulate double-strand break DNA repair. **2020**, 354, 187-213	1
675	Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer. **2020**, 10, 954	5
674	The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. **2020**, 18, 151	6
673	A GLOBAL DIGEST ON APPROACHES IN ADVANCED SOLID TUMORS. Report from the ESMO 2019 Congress, Barcelona, September 27th – October 1st 2019. **2020**, 13, 1-22	
672	PARP and PARG inhibitors in cancer treatment. **2020**, 34, 360-394	145
671	Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer. **2020**, 24, 3117-3127	6
670	Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib. **2020**, 25, 301-305	3
669	PARP inhibitors: a tsunami of indications in different malignancies. **2020**, 21, 221-230	7
668	Germline and Somatic Testing in Ovarian Cancer: Shifting Sands of Recommendations. **2020**, 156, 515-516	
667	Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management. **2020**, 10, 3390	13
666	A profile on the FoundationFocus CDxBRCA tests. **2020**, 20, 285-292	9
665	PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?. **2020**, 22, 29	6
664	Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. **2020**, 10, 2757	55
663	Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. **2020**, 38, 1164-1174	103
662	Genetic testing for epithelial ovarian cancer. **2020**, 65, 125-138	7
661	CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes. **2020**, 157, 405-410	18
660	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion Mutations among Patients with Advanced Solid Tumors. **2020**, 26, 2546-2555	18
659	Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. **2020**, 123, 109661	27

658	JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. **2020**, 126, 125-135	22
657	Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer. **2020**, 9,	8
656	A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. **2020**, 157, 214-221	1
655	Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. **2020**, 38, 1222-1245	86
654	Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis. **2020**, 147, 102888	9
653	Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. **2020**, 156, 561-567	11
652	MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC. **2020**, 13, 9	12
651	Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer. **2020**, 25, 1232-1238	9
650	Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?. **2020**, 21, 49	2
649	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. **2020**, 21, 710-722	28
648	Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial. **2020**, 21, 616-617	0
647	Targeting tumor microenvironment in ovarian cancer: Premise and promise. **2020**, 1873, 188361	34
646	Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. **2020** , 30, 903-915	15
645	Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. **2020**, 12,	7
644	Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. **2020**, 17,	12
643	Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. **2020**, 157, 578-584	11
642	Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore. **2020**, 16, 222-231	5
641	The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. **2020**, 27, 1780-1787	10

640	Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy. **2020**, 9, 537-551	2
639	The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. **2020**, 126, 2553-2560	2
638	Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers. **2021**, 39, 312-315	3
637	PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. **2021**, 45, 100696	6
636	Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials. **2021**, 46, 241-255	1
635	The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer. **2021**, 39, 231-241	2
634	PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis. **2021**, 128, 485-493	10
633	Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. **2021**, 34, 983-993	3
632	A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. **2021**, 32, 103-112	38
631	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. **2021**, 39, 966-977	42
630	Deep learning in cancer pathology: a new generation of clinical biomarkers. **2021**, 124, 686-696	69
629	Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery. **2021**, 28, 3637-3645	5
628	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. **2021**, 26, e394-e402	9
627	Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials. **2021**, 157, 103145	13
626	Current Ovarian Cancer Maintenance Strategies and Promising New Developments. **2021**, 12, 38-53	12
625	Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. **2021**, 160, 175-181	4
624	Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study. **2021**, 160, 227-233	0
623	Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). **2021**, 107, 100-109	4

622	Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: A single-center experience. **2021**, 148, 170-177	3
621	Zielgerichtete Therapie beim Ovarialkarzinom. **2021**, 54, 55-63	
620	Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. **2021**, 32, e82	0
619	The Prognostic Value of the CA-125 Elimination Rate (KELIM) as an Indicator of Response During Neo-Adjuvant Chemotherapy in Advanced-Stage Ovarian Cancer.	
618	Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers. **2021**, 16, 109-118	0
617	Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin. **2021**, 17, 9-19	1
616	Targeting DNA Repair and Chromatin Crosstalk in Cancer Therapy. **2021**, 13,	1
615	Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. **2021**, 30, 103-110	1
614	Screening for mutations in BRCA1 and BRCA2 genes and related perspectives for the healthcare system. **2021**, 18, 44-57	
613	SEOM clinical guideline in ovarian cancer (2020). **2021**, 23, 961-968	3
612	Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. **2021**, 20, 691-703	5
611	DNA Damage Repair Inhibitor for Breast Cancer Treatment. **2021**, 1187, 159-179	
610	Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials. **2021**, 46, 571-584	1
609	Therapie des Ovarialkarzinoms im Wandel. **2021**, 42, 34-37	
608	How to sequence treatment in relapsed ovarian cancer. **2021**, 17, 1-8	1
607	Dendritic Cell Vaccines in Ovarian Cancer. **2020**, 11, 613773	8
606	Comparisons of survival outcomes between bevacizumab and olaparib in -mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052). **2021**, 32, e90	0
605	Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. **2021**, 39, 796-802	0

604	PARP inhibitors in ovarian cancer: An overview of the practice-changing trials. **2021**, 60, 385-397	15
603	Signaling and Drug Resistance. **2021**, 79-94	
602	Chemoresistance in female-specific cancers and the associated anti-resistance therapies. **2021**, 49-69	
601	PARP inhibitors-understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia. **2021**, 8, e97-e99	
600	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. **2021**, 77, 67-82	5
599	Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. **2021**, 8, e122-e134	46
598	Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. **2021**, 13,	3
597	Molecular Signatures of Gynecological Cancers: Clinicians Perspective. **2021**, 12, 103-110	
596	Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy. **2021**, 49, 300060521991019	1
595	Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials. **2021**, 33, 452-461	1
594	Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation. **2021**, 13,	9
593	Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. **2020**, 10, 573801	5
592	Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. **2021**, 11, 4219	9
591	Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. **2021**, 158, 103209	5
590	Germline and tumor mutations in Chinese high grade serous ovarian cancer patients. **2021**, 9, 453	1
589	Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. **2021**, 13,	1
588	Tumour Versus Germline Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom. **2021**, 11,	0
587	Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission. **2021**, 31, 562-568	2

586	Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. **2021**, 127, 2432-2441	6
585	Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles' Heel. **2021**, 13,	7
584	Structural Variants at the Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. **2021**, 27, 3201-3214	1
583	Targeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive Peptides. **2021**, 10,	9
582	Germline Mutations in Other Homologous Recombination Repair-Related Genes Than : Predictive or Prognostic Factors?. **2021**, 11,	3
581	C□cer de ovario. **2021**, 13, 1518-1526	
580	PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival. **2021** , 13, 8975-8988	2
579	Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review. **2021**, 9, 510	5
578	Reacci□ liquenoide inducida por niraparib. **2021**, 36, 204-206	
577	Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know. **2021**, 30, 543-554	5
576	ARRDC3 as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer Based on Data Mining. **2021**, 14, 967-981	0
575	Hereditary breast cancer and ovarian cancer: clinical course and treatment. **2021**, 16, 54-65	
574	Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays. **2021**, 125, 7-14	5
573	Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. **2021**, 55, 100744	12
572	Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway. **2021**, 22,	3
571	Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review. **2021**, 13,	3
570	Personalized and targeted therapies. **2021**,	
569	Medikamentö□e Therapie des Ovarialkarzinoms. **2021**, 15, 143-162	

568	PARP inhibitors: shifting the paradigm in the ́treatment of pancreatic cancer. **2021**, 38, 61	0
567	Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer. **2021**, 13, 3081-3100	6
566	Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy. **2021**, 22,	13
565	Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer. **2021**, 304, 1055-1063	2
564	Conditional Relative Survival of Ovarian Cancer: A Korean National Cancer Registry Study. **2021**, 11, 639839	3
563	Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis. **2022**, 56, 27-34	1
562	Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations. **2021**, 11,	0
561	FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. **2021**, 13,	5
560	Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial. **2021**, 32, 512-521	25
559	Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing. **2021**, 14, 61	2
558	Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study. **2021**, 14, 706-715	3
557	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. **2021**, 22, 632-642	14
556	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). **2021**, 12, 2487	24
555	Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art. **2021**, 13,	3
554	Management of advanced ovarian cancer in Spain: an expert Delphi consensus. **2021**, 14, 72	1
553	MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer. **2021**, 12,	1
552	Mammary lineage dictates homologous recombination repair and PARP inhibitor vulnerability.	1
551	The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value. **2021**, 161, 491-495	

550	Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. **2021**, 31, 1031-1036	1
549	The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers. **2021**,	1
548	Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors. **2021**, 22,	1
547	Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). **2021**, 21, 593	7
546	Present and Future for PARP Inhibitors in Ovarian Cancer. **2021**, 1, 139-154	
545	Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. **2021**, 304, 285-296	2
544	FLABRA, frontline approach for testing in an ovarian cancer population: a Latin America epidemiologic study. **2021**, 17, 1601-1609	
543	mutated pancreatic cancer: A change is coming. **2021**, 27, 1943-1958	10
542	Targeted Therapies in Older Adults With Solid Tumors. **2021**, 39, 2128-2137	4
541	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. **2021**, 42, 785-793	1
540	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. **2021**, 149, 134-152	13
539	PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data. **2021**, 117, 105292	4
538	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. **2021**, 97, 102187	9
537	Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. **2021**, 22, 981-1003	2
536	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. **2021**, 31, 949-958	0
535	The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?. **2021**, 6, 100144	12
534	Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices. **2021**, 6, 100135	1
533	Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. **2021**, 161, 653-659	6

532	PARP inhibitor associated treatment related myeloid neoplasms: What was a "Rare" complication may be less so. **2021**, 161, 639-641	1
531	An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers. **2021**, 13,	
530	The systemic treatment of recurrent ovarian cancer revisited. **2021**, 32, 710-725	13
529	The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks. **2021**, 13,	2
528	PARP inhibitors in gastric cancer: beacon of hope. **2021**, 40, 211	9
527	PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor □Positive Breast Cancer Cells. **2021**, 19, 1688-1698	1
526	Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system. **2021**, 10781552211024728	
525	Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors against Cancer. **2021**,	1
524	Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer. **2021**,	1
523	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. **2021**, 11,	2
522	Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. **2021**, 9, 593-600	22
521	Frontline Maintenance Treatment for Ovarian Cancer. **2021**, 23, 97	1
520	Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?. **2021**, 11, 683057	
519	A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. **2021**, 2, 598-610	39
518	Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study. **2021**, 20, 1735-1742	1
517	The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality. **2021**, 11, 689829	4
516	Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology. **2021**, 9,	6
515	PARP inhibitors and immunotherapy in ovarian and endometrial cancers. **2021**, 94, 20210002	2

514	Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies. **2021**, 30, 695-707	1
513	Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma. **2021**, 5,	1
512	Relevance of Platinum-free Interval and Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g Advanced Breast Cancer (BROCADE3 Crossover). **2021**, 27, 4983-4993	3
511	Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary´analysis of FORWARD I. **2021**, 32, 757-765	17
510	Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. **2021**, 163, 50-56	0
509	Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. **2021**,	2
508	Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. **2021**, 225, 68.e1-68.e11	3
507	Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan. **2021**, 60, 634-638	0
506	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. **2021**, 18, 773-791	31
505	Phase 2 non-randomised trial of secondary cytoreduction and hyperthermic intraperitoneal chemotherapy in recurrent platinum-sensitive ovarian cancer. **2021**, 15, 1260	
504	Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. **2021**, 163, 64-71	0
503	Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes. **2021**, 12,	3
502	Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancer. **2021**, 15, 1262	0
501	Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. **2021**, 163, 41-49	1
500	Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis. **2021**, 11, 638295	0
499	Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores. **2021**, 6, 100229	2
498	Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. **2021**, 31, 1348-1355	0
497	Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer. **2021**, 27, 5681-5687	5

496	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. **2021**, 162, 375-381	1
495	Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. **2021**, 9,	3
494	Multi-layered chromatin proteomics identifies cell vulnerabilities in DNA repair.	1
493	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. **2021**, 16, 1403-1414	0
492	Cytotoxic and targeted therapy for BRCA1/2-driven cancers. **2021**, 19, 36	3
491	Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). **2021**, 5,	6
490	Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms. **2021**, 22, 777-790	0
489	Ovarian cancer: epigenetics, drug resistance, and progression. **2021**, 21, 434	7
488	An update of new small-molecule anticancer drugs approved from 2015 to 2020. **2021**, 220, 113473	11
487	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in , , or. **2021**, 39, 2497-2505	34
486	A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors. **2021**, 88, 887-897	0
485	Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials. **2021**, 9, 1229	2
484	A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA. **2021**, 1-13	1
483	Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey. **2021**, 31, 1363-1368	0
482	The evolving role of PARP inhibitors in advanced ovarian cancer. **2021**, 12, 82-104	
481	Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study. **2021**, 13,	8
480	Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. **2021**, 5,	3
479	Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. **2021**, 162, 482-495	4

478	Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status. **2021**, 10,	
477	Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. **2021**, 162, 728-734	1
476	Reduces Aggressive Phenotype and Induces in Ovarian Cancer Cells. **2021**, 13,	1
475	Determinants of Homologous Recombination Deficiency in Pancreatic Cancer. **2021**, 13,	4
474	Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers. **2021**, 163, 220-228	0
473	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. **2021**, 31, 1589-1594	6
472	Prévention et traitement des effets secondaires des inhibiteurs de la poly-ADP-ribose-polymérase-1 (iPARP) dans les cancers du sein et de l'ovaire. **2021**, 12, 144-150	
471	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. **2021**, 10, 7162-7173	2
470	Prevention and treatment of the side effects of poly-ADP-ribose polymerase-1 inhibitors (iPARP) in breast and ovarian cancer. **2021**, 12, e36-e42	
469	Ovarian Cancer-Specific -like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. **2021**, 27, 6559-6569	2
468	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. **2021**, 27, 6106-6114	1
467	Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. **2021**,	0
466	Synthetic Lethality in Ovarian Cancer. **2021**, 20, 2117-2128	6
465	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. **2021**, 99, 102255	2
464	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. **2021**, 154, 190-200	1
463	Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines. **2021**, 22,	2
462	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. **2021**, 163, 490-497	3
461	Cell-stiffness and morphological architectural patterns in clinical samples of high grade serous ovarian cancers. **2021**, 37, 102452	4

460	Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. **2021**, 7, 958-970	3
459	Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers. **2021**, 163, 498-505	2
458	Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review. **2021**, 60, 26-34	3
457	Malignant diseases of the ovary, fallopian tube, and peritoneum. **2022**, 707-753.e7	0
456	Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. **2021**, 11,	15
455	The role of PARP inhibitors in mutated pancreatic cancer. **2021**, 14, 17562848211014818	9
454	A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). **2021**, 32, e31	4
453	Encyclopedia of Molecular Pharmacology. **2021**, 1-12	
452	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. **2020**, 152, 102973	9
451	PARP inhibition in the ovarian cancer patient: Current approvals and future directions. **2020**, 213, 107588	4
450	Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. **2020**, 40,	10
449	Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. **2021**, 113, 917-923	8
448	Making radiation therapy more effective in the era of precision medicine. **2020**, 3, 272-283	1
447	Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. **2021**, 137, 108-121	25
446	Innovations in targeted therapies for triple negative breast cancer. **2021**, 33, 34-47	3
445	Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors.	6
444	Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancer.	2
443	Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?. **2020**, 177, 3635-3645	29

442	Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. **2020**, 30, 89-93	13
441	EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. **2020**, 26, 4206-4215	30
440	The evolving landscape of predictive biomarkers of response to PARP inhibitors. **2018**, 128, 1727-1730	32
439	A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. **2018**, 128, 2116-2126	60
438	Renal insufficiency in patients on PARP inhibitors: Case-based review of possible mechanisms and management. **2021**, 5, 8-12	1
437	Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series. **2020**, 21, e927008	3
436	Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. **2019**, 10, 2855-2868	7
435	PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.. **2019**, 2, 665-679	8
434	Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology.. **2019**, 2, 608-617	1
433	Current practices on genetic testing in ovarian cancer. **2020**, 8, 1703	4
432	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. **2018**, 6, 143	6
431	Biliary tract cancer prognostic and predictive genomics. **2019**, 8, 42	7
430	Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. **2020**, 32, 370-382	8
429	Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic -mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review. **2020**, 13, 12979-12986	6
428	Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. **2020**, 21, 167-178	7
427	Hereditary ovarian cancers: state of the art. **2019**, 110, 301-319	11
426	New medical approaches in advanced ovarian cancer. **2019**, 110, 367-384	3
425	PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. **2020**, 12,	49

424	The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. **2020**, 12,	13
423	Wise Management of Ovarian Cancer: On the Cutting Edge. **2020**, 10,	32
422	The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. **2020**, 3, 157-164	2
421	Major clinical research advances in gynecologic cancer in 2019. **2020**, 31, e48	7
420	Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer. **2020**, 19, 2629-2638	5
419	PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective. **2020**, 20, 90	5
418	Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. **2020**, 18, 36-43	11
417	Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer. **2019**, 11, e5197	3
416	Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes. **2021**, 135-166	
415	Cutting-Edge Technologies for Ovarian Cancer: An Overview of the Impact of Genetic Testing, Next-Generation Sequencing, and Single-Cell Analysis. **2021**, 203-229	
414	Estrogens and the Schrödinger's Cat in the Ovarian Tumor Microenvironment. **2021**, 13,	1
413	The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing. **2021**, 40, 338	3
412	PARP Inhibitors and Haematological Malignancies-Friend or Foe?. **2021**, 13,	1
411	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. **2021**, 155 Suppl 1, 61-85	14
410	Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). **2021**, 31, 1369-1373	1
409	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. **2021**, 163, 246-253	8
408	Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents. **2021**, 11, 745981	0
407	Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond. **2021**, 2021, 1682532	1

406	Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction. **2021**, 11, 675972	1
405	Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. **2022**, 49, 61-81	1
404	A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes. **2021**, 9,	0
403	Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue - A pilot study. **2021**, 123, 104705	
402	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. **2021**,	6
401	Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. **2021**, 112, 5055-5067	1
400	Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers. **2021**, 12,	0
399	Identification of Novel Drug Candidate for Epithelial Ovarian Cancer Investigation and Validation. **2021**, 11, 745590	0
398	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. **2021**, 13,	1
397	Poly(ADP-Ribose) Polymerase Inhibitors and Myeloid Neoplasm Risk-Clues to a Mechanistic Connection?. **2021**,	
396	Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing. **2021**, 13,	
395	PARP inhibitors: clinical relevance and the role of multidisciplinary cancer teams on drug safety. **2021**, 1-11	0
394	The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit. **2021**,	2
393	Gynecological Symptoms. **2018**, 505-526	
392	Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations. **2018**, 7, 212558	2
391	Maintenance Treatment for Recurrent Ovarian Carcinoma Evidence Supporting the Efficacy and Safety of PARP Inhibitors. **2019**, 15, 29	0
390	Rucaparib and Niraparib in Advanced Ovarian Cancer. **2019**, 10, 402-408	0
389	Molecular Testing in Ovarian Cancer: Recommendations and Treatment Considerations. **2020**, 171-186	

388	Practical aspects of treating relapsed BRCA-associated ovarian cancer. **2019**, 144-149	
387	Germline BRCA, Chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.	
386	Germline BRCA, Chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.	
385	Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma.	
384	Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51.	
383	Unravelling the Mysteries of the Human Brain (Vol. 24, No. 8, Full Issue). **2020**, 24,	
382	USP48 Sustains Chemoresistance and Metastasis in Ovarian Cancer. **2020**, 20, 689-699	1
381	U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review. **2021**,	1
380	BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials. **2021**, 11, 718871	1
379	Adverse events of targeted therapies approved for women's cancers.. **2021**, 7, 552-559	
378	Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls. **2021**, 163, 217-219	0
377	Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data. **2021**, 1	1
376	Ovarian cancer risk assessment in the era of next-generation sequencing. **2020**, 8, 1704	0
375	Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. **2021**, 16, 59-68	4
374	Alle Aspekte der Nachsorge in der gynkologischen Onkologie am Beispiel des Ovarialkarzinoms. **2021**, 54, 99-106	1
373	A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial. **2021**, 31, 617-622	1
372	Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine. **2020**,	3
371	Breast metastasis from pelvic high-grade serous adenocarcinoma: a report of two cases. **2020**, 6, 317	0

370	Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance. **2021**, 33, 19-25	2
369	Germline BRCA, Chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.	
368	Neue Arzneimittel 2019. **2020**, 43-150	2
367	Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?. **2020**, 31, e95	
366	ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738.	
365	Long-term response to Olaparib in carcinomatous meningitis of a mutated ovarian cancer: A case report. **2020**, 13, 73-75	4
364	Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma. **2021**, 11, 666815	2
363	Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer. **2021**, 12, 771836	
362	Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients.. **2021**, 28, 4446-4456	
361	Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss of Heterozygosity Score. **2021**,	9
360	Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea. **2020**, 52, 1229-1241	2
359	Using PARP Inhibitors in Advanced Ovarian Cancer. **2018**, 32, 339-43	19
358	Treatment algorithm in patients with ovarian cancer. **2020**, 12, 227-239	1
357	TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models. **2021**, 11, 1632-1645	1
356	Efficacy of Poly(ADP-Ribose) Polymerase Inhibitors for Hereditary Ovarian Cancer. **2021**, 313-324	
355	PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review. **2021**, 108, 35-80	2
354	Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.. **2021**, 11, 785102	0
353	Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy. **2021**, 23, 148	1

352	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies.. **2021**, 28, 4894-4928	
351	[Place of PARP inhibitors in the treatment of endometrial and cervical cancers]. **2021**,	
350	Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?. **2021**, 13,	3
349	Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.. **2021**, 12, 743073	0
348	BRCA1/ATF1-Mediated Transactivation is Involved in Resistance to PARP Inhibitors and Cisplatin. **2021**, 1, 90-105	0
347	[Homologous recombination deficiency and PARP inhibitors in therapeutics]. **2021**,	0
346	Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. **2021**,	0
345	Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer. **2021**, 8, 762741	0
344	Structure-based virtual screening towards the discovery of novel ́FOXM1 ̂inhibitors. **2021**,	0
343	Alle Aspekte der Nachsorge in der gyn□kologischen Onkologie am Beispiel des Ovarialkarzinoms. **2021**, 31, 129	
342	Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. **2021**, 159, 283-295	1
341	European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer. **2021**,	7
340	Hereditary Ovarian Cancer. **2021**, 93-106	
339	DNA Damage Response. **2021**, 536-547	
338	Germline Findings Through Precision Oncology for Ovarian Cancer. **2021**, 211-226	
337	Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.. **2022**, 6, e2000508	1
336	Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.. **2021**, 11, 746571	0
335	Homologous recombination deficiency testing in first-line ovarian cancer.. **2022**,	1

334	Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.. **2021**, 7, 100311	1
333	Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.. **2021**, 24, 63-75	1
332	Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.. **2021**, 27, 432-440	0
331	PARP Inhibitors in Pancreatic Cancer.. **2021**, 27, 465-475	1
330	New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.. **2021**, 27, 441-456	1
329	Beyond BRCA1/2: Homologous Recombination Repair Genetic Profile in a Large Cohort of Apulian Ovarian Cancers.. **2022**, 14,	0
328	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.. **2022**, 14,	0
327	Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.. **2022**, 22, 13	1
326	Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis.. **2022**, 29, 321-336	1
325	Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary.. **2022**, 27, e9-e17	2
324	A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.. **2021**,	1
323	Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.. **2022**,	1
322	Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.. **2022**,	2
321	Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.. **2022**,	0
320	PARP mediated DNA damage response, genomic stability and immune responses.. **2021**,	3
319	Value of the loss of heterozygosity to BRCA1 variant classification.. **2022**, 8, 9	
318	DNA Damage Repair in Brain Tumor Immunotherapy.. **2021**, 12, 829268	
317	Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.. **2022**, 22, 100	1

316	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.. **2021**,	1
315	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.. **2021**,	1
314	Testing for homologous recombination deficiency - does it provide new insights for the use of veliparib?. **2022**, 164, 243-244	
313	Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathlological Characteristics.. **2022**, 12, 709645	0
312	Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer. **2021**,	0
311	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.. **2021**, JCO2101657	3
310	Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience.. **2022**, 40, 100939	2
309	Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.. **2022**,	1
308	MTPpilot: an interactive software for visualization of NGS results in molecular tumor boards.	
307	Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).. **2022**,	0
306	The DNA-PK inhibitor AZD7648 sensitizes patient derived ovarian cancer xenografts to pegylated liposomal doxorubicin and olaparib preventing abdominal metastases.. **2022**,	0
305	Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.. **2022**,	0
304	Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review.. **2022**,	2
303	Aktuelles zur systemischen Rezidivtherapie des epithelialen Ovarialkarzinoms. **2022**, 55, 176	
302	Perspectives on PARP Inhibitor Combinations for Ovarian Cancer.. **2021**, 11, 754524	0
301	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. **2021**, 168, 103539	4
300	The Use of Targeted Agents in the Treatment of Gynecologic Cancers.. **2022**, 23, 15	0
299	Identification of the c.829_832delAATA Deletion Variants in the Gene Associated with Hereditary Breast/Ovarian Cancer - Case Report.. **2022**, 10, 33-38	

298	PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.. **2022**,	0
297	The BRCA Gene in Epithelial Ovarian Cancer.. **2022**, 14,	1
296	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.. **2022**, 14,	1
295	PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components.. **2022**, 15, 165-180	1
294	Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.. **2022**, 14,	0
293	RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?. **2021**,	2
292	Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives.. **2022**, 12, 831612	0
291	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities.. **2022**, 14,	3
290	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.. **2022**, 14,	4
289	Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.. **2022**, 2, CD007929	4
288	Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.. **2022**, 14, 673-686	0
287	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.. **2022**, 14,	1
286	PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.. **2022**,	
285	Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.. **2022**, 1	0
284	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.. **2022**, 23,	1
283	BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?. **2022** ,	1
282	Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.. **2022**,	1
281	Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.. **2022**, 14,	1

280	Germline Pathogenic Variants in and : Malignancies Beyond Female Breast and Ovarian Cancers.. **2022**, JCO2200003	
279	Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.. **2022**,	1
278	Novel Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research.. **2022**, 12, 837233	0
277	Clinical and analytical validation of FoundationOnefi CDx, a comprehensive genomic profiling assay for solid tumors.. **2022**, 17, e0264138	6
276	DNA repair defects in cancer and therapeutic opportunities.. **2022**, 36, 278-293	2
275	Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.. **2022**, 22, 346	1
274	Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models.. **2022**, 12, 862321	0
273	Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy.. **2022**, 12,	2
272	Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.. **2022**,	
271	Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma.. **2022**, 15, 51	
270	Practice guidelines for tumour testing in ovarian cancer.. **2022**,	1
269	PARP inhibition in breast cancer: progress made and future hopes.. **2022**, 8, 47	6
268	Templated insertions are associated specifically with BRCA2 deficiency and overall survival in advanced ovarian cancer.. **2022**,	1
267	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.. **2022**, JCO2102767	7
266	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.. **2022**, 166, 87-99	2
265	Development of Next-Generation Poly(ADP-Ribose) Polymerase 1-Selective Inhibitors.. **2021**, 27, 521-528	1
264	Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy.. **2021**, 27, 506-510	
263	With Our Powers Combined: Exploring PARP Inhibitors and Immunotherapy.. **2021**, 27, 511-520	

262	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.. **2021**, 13,	6
261	Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.. **2021**, 13,	1
260	Prise en charge m□dicale de la r□cidive du cancer □pith□lial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.. **2021**, 108, S22-S32	
259	DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?. **2021**, 10,	0
258	The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.. **2021**, 14, 206	2
257	Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.. **2022**, 19, 60-78	0
256	Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.. **2021**, 10,	1
255	Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review).. **2022**, 16, 29	0
254	Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.. **2021**, 14,	0
253	Identification of molecular subtypes and prognostic signature for hepatocellular carcinoma based on genes associated with homologous recombination deficiency.. **2021**, 11, 24022	1
252	Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.. **2021**, 11, 603591	2
251	Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report.. **2021**, 12, 3133-3140	0
250	Current trends in chemotherapy for advanced ovarian cancer.. **2022**,	
249	Appropriate Selection of PARP Inhibitors in Ovarian Cancer.. **2022**, 23, 887	2
248	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.. **2022**, 89, 721	0
247	Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.. **2022**,	0
246	Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.. **2022**, JCO2101801	1
245	Tumor genetics and individualized therapy.	

244	Rucaparib and olaparib for the treatment of prostate cancer: A clinician's guide to choice of therapy.. **2022**, 10781552221094308	0
243	Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.. **2022**, JCO2101511	3
242	A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer Patients.. **2022**, 8971900221088793	0
241	Targeting mutations in cancer.. **2022**, 132,	3
240	Data_Sheet_1.docx. **2020**,	
239	Data_Sheet_1.docx. **2020**,	
238	Image_1.JPEG. **2020**,	
237	Table_1.DOC. **2020**,	
236	Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.. **2022**, 106232	1
235	Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas.. **2022**, 6, 29	0
234	Characterization of anticancer drug resistance by Reverse Phase Protein Array: new targets and strategies.. **2022**,	0
233	Altered Signaling Pathways Revealed by Comprehensive Genomic Profiling in Patients With Unknown Primary Tumors.. **2022**, 12, 753311	0
232	Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer.. **2022**, 12, 337-354	
231	Clinical Evidence in Gynaeoncology: Sources and Application. **2022**, 35-49	
230	Chemotherapy in Gynaecological Cancers and Newer Developments. **2022**, 123-138	
229	Role of Genetics in Gynaecological Cancers. **2022**, 207-219	
228	Immune-and Metabolism-Associated Molecular Classification of Ovarian Cancer. **2022**, 12,	0
227	Combinatorial Treatment with Poly(ADP-ribose) Polymerase-1 Inhibitors and Cisplatin Attenuates Cervical Cancer Growth Through Fos-Driven Changes in Gene Expression.. **2022**,	0

226	The Landscape of Personalized Medicine in Gynecologic Cancer. **2022**, 2, 99-105	
225	Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.. **2022**, 22, 508	0
224	The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.. **2022**, 1-8	0
223	Ovarian, Vaginal, and Vulvar Cancer. **2022**, 317-339	
222	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. **2022**, 14, 2470	0
221	The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling.. **2022**,	0
220	Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance. **2022**, 14, 2504	1
219	Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis. **2022**, 12,	
218	The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. 1-9	0
217	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. **2022**, 7, 100459	1
216	A Randomised, Multi-centre Phase II Trial of Weekly Paclitaxel and Vistusertib in Platinum-Resistant Ovarian High-Grade Serous Carcinoma: OCTOPUS Arm 1.	
215	Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions. **2022**,	
214	Salt-Inducible Kinase 2-Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis. 2202260	0
213	Is there a low Risk Patient Population in Advanced Epithelial Ovarian Cancer?: A Critical Analysis. **2022**,	0
212	Comprehensive Network Analysis of Dysregulated Genes Revealed MNX1-AS1/ hsa-miR-4697-3p/ HOXB13 Axis in OC Chemotherapy Response.	0
211	Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12. 13,	1
210	Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. **2022**, 170, 169-178	0
209	Gynecologic malignancies. **2023**, 310-318	

208	Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant. **2022**, 32, 100587	0
207	Molecular analysis of ascitic fluid cytology reflects genetic changes of malignancies of the ovary equivalent to surgically resected specimens.	0
206	Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery. 9,	
205	Interpreting Nonrandomized Clinical Trial Data in Low-Grade Sarcoma: Differentiating Clinical Benefit From Indolent Disease Is Key. **2022**,	
204	Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data. 13,	1
203	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA[MONO/GOG-3020/ENGOT-ov45).	9
202	PARP Inhibitors: A New Horizon for Patients with Prostate Cancer. **2022**, 10, 1416	3
201	Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer.	
200	Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis. 12,	1
199	A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. **2022**, 29, 4354-4369	
198	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. **2022**, 13,	3
197	Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.	0
196	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. **2022**, 14, 2950	0
195	Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer. jclinpath-2022-208369	
194	Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. **2022**, 171, 232-241	0
193	Hyperthermia synergistically enhances antitumor efficacy of PARP inhibitor through impacting homologous recombination repair and oxidative stress in ́vitro. **2022**, 619, 49-55	
192	PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers. **2022**,	1
191	Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion. **2022**, 14, 111-120	0

190	Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. **2022**,	2
189	Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials. **2022**, 10,	0
188	Low BRCA1/2 germline mutation rate in a French-Canadian population with a diagnosis of epithelial tubo-ovarian carcinoma. **2022**,	
187	Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea. **2022**,	
186	Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis. **2022**,	0
185	Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes.	2
184	Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer. **2022**, 19, 8577	2
183	Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. **2022**, 10, e005041	3
182	Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review. 13,	
181	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. **2022**,	1
180	Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context. **2022**, 18, 2505-2536	0
179	JMJD8 Is an M2 Macrophage Biomarker, and It Associates With DNA Damage Repair to Facilitate Stemness Maintenance, Chemoresistance, and Immunosuppression in Pan-Cancer. 13,	0
178	The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. **2022**, 23, 8125	2
177	Comprehensive Genomic Profiling in the Management of Ovarian Cancer: National Results from Croatia. **2022**, 12, 1176	
176	Health-related quality of life analysis in ovarian cancer clinical trials involving PARP inhibitors: a critical methodological perspective.	0
175	Maintenance therapy for newly diagnosed epithelial ovarian cancer: a review. **2022**, 15,	0
174	Molecular Biomarkers in Cancer. **2022**, 12, 1021	2
173	PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications. **2022**, 153, 113458	0

172	Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial. 12,	0
171	Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynäkologische Onkologie intergroup analysis. ijgc-2022-003637	
170	Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database.	1
169	A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer. **2022**,	
168	PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them. **2022**, 23, 8412	3
167	Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. 12,	0
166	Low BRCA1/2 germline mutation rate in a French-Canadian population with a diagnosis of epithelial tubo-ovarian carcinoma. **2022**,	
165	Personalisierte Therapie beim metastasierten Urothelkarzinom – Vision oder Wirklichkeit?. **2022**, 28, 805-811	
164	Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors. 109158182211213	
163	A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.	
162	Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation. 13,	
161	MTPpilot: An Interactive Software for Visualization of Next-Generation Sequencing Results in Molecular Tumor Boards. **2022**,	
160	MicroRNA-dependent inhibition of WEE1 controls cancer stem-like characteristics and malignant behavior in ovarian cancer. **2022**,	0
159	Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma. **2022**, 13, 1398	
158	Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma. **2022**, 2022, 1-27	
157	BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. **2022**, 14, 3888	5
156	Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers. **2022**, 13,	1
155	Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer.	

154	Phase I trial of ribociclib with platinum chemotherapy in recurrent ovarian cancer.	1
153	A Japanese nationwide observational multicenter study of tumor BRCA1 /2 variant testing in advanced ovarian cancer.	0
152	Primary results of rucaparib in ovarian cancer´.	
151	Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma.	
150	Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.	0
149	A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.	0
148	Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes. **2022**, 153, 113504	
147	Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. **2022**, 52, 101595	1
146	Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system. 13,	1
145	Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting. **2022**, 14, 4414	0
144	Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis. **2022**, 7, 100558	0
143	Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics. **2022**, 14, 175883592211180	0
142	Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial. **2022**, 14, 175883592211261	0
141	Homologous Recombination Deficiency Scar: Mutations and Beyond□Implications for Precision Oncology. **2022**, 14, 4157	0
140	Gestion pratique des inhibiteurs de PARP´: Un consensus national DELPHI. **2022**,	0
139	Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. OF1-OF10	0
138	A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i>-associated ovarian cancer. **2022**, 21, 156-164	0
137	Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.	0

136	HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data. 13,	0
135	Leveraging an Informatics Approach to Identify an Unmet Clinical Need for BRCA1/2 Testing Among Patients With Ovarian Cancer. **2022**,	0
134	PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.	0
133	Therapy for Recurrent High-Grade Epithelial Ovarian Cancer□The Current Status and Future Trends.	0
132	Preclinical and clinical trial results using Talazoparib and Low-Dose Chemotherapy.	0
131	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20´years□experience. **2022**, 22,	0
130	Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers.	0
129	Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer. **2022**,	0
128	Klonale H□hatopoese und solide Neoplasien.	0
127	Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. **2022**, 14, 4621	0
126	Epithelial ovarian cancer: Review article. **2022**, 100629	1
125	High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancer. **2022**,	2
124	Reply to C. Marchetti et al.	0
123	Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors. Volume 15, 1105-1117	1
122	Functional homologous recombination assay on FFPE specimens of advanced high-grade serous ovarian cancer predicts clinical outcomes.	0
121	Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed. 13,	0
120	Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective. **2022**, 33,	1
119	Hereditary Ovarian Cancer. **2022**, 43-55	0

118	Management of Recurrent Ovarian Cancer. **2022**, 121-128	0
117	Personalized Treatment in Ovarian Cancer. **2022**, 1-19	0
116	Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan. 34,	0
115	Clinical Relevance of BRCA1/2 Pathogenic Variants and Impaired DNA Repair Pathways in Ovarian Carcinomas. **2022**, 59-76	0
114	Selective PARP1 Inhibitors, PARP1-based Dual-Target Inhibitors, PROTAC PARP1 Degraders, and Prodrugs of PARP1 Inhibitors for Cancer Therapy. **2022**, 106529	1
113	SMARAGD 1Neue Registerplattform zum Ovarial- und Endometriumkarzinom gestartet.	0
112	Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. **2022**, 29,	0
111	State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. **2022**,	0
110	A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. **2022**, 3, 1181-1191	1
109	Mfn2-mediated mitochondrial fusion promotes autophagy and suppresses ovarian cancer progression by reducing ROS through AMPK/mTOR/ERK signaling. **2022**, 79,	1
108	Precision Medicine in Oncology Drug Development. 1-15	0
107	Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.	1
106	Small molecule inhibitors targeting the cancers. **2022**, 3,	0
105	Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis. ijgc-2022-003614	0
104	Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer. **2022**, 13,	0
103	Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. **2022**,	0
102	Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. 1-23	0
101	Integrative Genomic Tests in Clinical Oncology. **2022**, 23, 13129	0

100	Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer. **2022**,	0
99	Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?. **2022**,	1
98	Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma. 12,	0
97	Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: a current perspective. **2022**,	0
96	Exploring the DNA damage response pathway for synthetic lethality.	0
95	Synthesis and antineoplastic activity of ethylene glycol phenyl aminoethyl ether derivatives as FOXM1 inhibitors. **2022**, 244, 114877	0
94	NAD+ metabolism in peripheral neuropathic pain. **2022**, 161, 105435	0
93	Tratamiento m□dico de los c□nceres epiteliales de ovario. **2022**, 58, 1-12	0
92	A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. **2022**, 206, 115329	0
91	Epithelial ovarian cancer. **2023**, 250-281.e8	0
90	Targeted therapy and molecular genetics. **2023**, 464-488.e11	0
89	Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.	0
88	A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.	0
87	Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer. 107815522211377	0
86	A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis. 13,	0
85	Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain □A GEICO study. **2022**, 22,	0
84	Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors.	0
83	Design and reporting of phase III oncology trials with prospective biomarker validation.	0

82	Clinical Significance of Tie-2-Expressing Monocytes/Macrophages and Angiopoietins in the Progression of Ovarian Cancer—State-of-the-Art. **2022**, 11, 3851	0
81	DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. **2022**, 23, 14672	0
80	Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. **2022**,	0
79	Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. **2022**, 14, 5795	0
78	Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial.	0
77	Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test. **2022**, 22,	0
76	Cost-effectiveness of PARP inhibitors in malignancies: A systematic review. **2022**, 17, e0279286	1
75	Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial. **2022**,	0
74	Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations. **2022**, 22,	0
73	Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.	0
72	Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!. **2023**, 15, 43	0
71	The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. 9,	0
70	Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report. 12,	0
69	First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer. **2022**,	0
68	The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data. **2022**, 167, 401-403	0
67	Towards Personalized Management of Ovarian Cancer. Volume 14, 3469-3483	0
66	Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.	0
65	Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case–control study. ijgc-2022-003764	0

64	Best original research presented at the 23rd European Congress on Gynaecological Oncology□Best of ESGO 2022. ijgc-2022-004184	0
63	Advances in small molecule maintenance therapies for high-grade serous ovarian cancer. 1-8	0
62	Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. **2023**,	0
61	Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. **2023**, 16,	0
60	Molecular Profiling of Gynaecological Cancer and Breast Cancer. **2022**, 9-24	0
59	DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities. **2023**, 15, 448	0
58	Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. 106002802211491	0
57	Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.	0
56	Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society. 030089162211468	0
55	Efficacy of chemotherapy according toBRCAstatus in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse. ijgc-2022-003993	0
54	Identification of the diagnostic genes and immune cell infiltration characteristics of gastric cancer using bioinformatics analysis and machine learning. 13,	0
53	Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.	0
52	The Impact of Homologous Recombination Deficiency on First-line Adjuvant Chemotherapy and First-line PARPi Maintenance Therapy in Chinese Patients with Epithelial Ovarian Cancer.	0
51	Multi-layered chromatin proteomics identifies cell vulnerabilities in DNA repair.	0
50	Klonale H□matopoese und solide Neoplasien.	0
49	CD8□ dendritic cells potentiate antitumor and immune activities against murine ovarian cancers. **2023**, 13,	0
48	Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish Expanded-Access Programme. **2022**,	0
47	Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors.	0

46	PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. ijgc-2022-003990	0
45	Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. **2023**,	0
44	Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?. **2023**, 15, 730	0
43	Quality of Life is Essential: Implications for Diagnosis and Treatment for BRCA1/2 Germline Mutations.	0
42	Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305. 13,	0
41	Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. **2023**,	0
40	Increase in serum creatinine levels after PARP inhibitor treatment. **2023**, 43,	0
39	Myeloid neoplasms post PARP inhibitors for ovarian cancer. ijgc-2022-004190	0
38	Homologous Recombination Deficiency in Ovarian Cancer: From the Biological Rationale to Current Diagnostic Approaches. **2023**, 13, 284	0
37	Safety and management of niraparib monotherapy in ovarian cancer clinical trials. ijgc-2022-004079	0
36	Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. **2023**, 172, 121-129	0
35	The Role of PARP Inhibitors in the Treatment of Advanced Epithelial Ovarian Carcinoma. **2022**,	0
34	Recent Advances in Gynaecological Oncology. **2022**, 475-494	0
33	Fallopian Tube Carcinoma. **2022**, 357-361	0
32	Epithelial Ovarian Cancer. **2022**, 291-323	0
31	The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. **2023**, 23, 317-325	0
30	Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study. **2023**, 15, 1032	0
29	Survival outcomes in patients withBRCAmutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors. ijgc-2022-003903	0

28	Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601. ijgc-2022-004028	0
27	The PARP inhibitor Rucaparib synergizes with radiation to attenuate atypical teratoid rhabdoid tumor growth. **2023**, 5,	0
26	Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. **2023**, 15,	1
25	Mainstream genetic testing for high-grade ovarian, tubal and peritoneal cancers: A tertiary referral centre experience. **2023**, 63, 241-246	0
24	Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. **2023**,	0
23	Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies. **2023**, 28, 293-306	0
22	Amplified therapeutic targets in high-grade serous ovarian carcinoma a review of the literature with quantitative appraisal.	0
21	PARP inhibitor-related haemorrhages: What does the real-world study say?. 13,	0
20	D ficit de la recombinaison homologue dans les cancers pith liaux de l vaire´: de la caract isation mol culaire au parcours des patientes. **2023**, 110, 371-381	0
19	Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. **2023**, 15, 175883592311576	0
18	Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3. **2023**, 34,	0
17	Molecular typing guiding treatment and prognosis of endometrial cancer. **2023**, 3, 7-17	0
16	Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis. **2023**, 8, 101154	0
15	The biology and treatment of leiomyosarcomas. **2023**, 184, 103955	0
14	Personalized Systemic Therapies in Hereditary Cancer Syndromes. **2023**, 14, 684	0
13	A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer. **2023**, 46, 101162	0
12	Outcomes and endpoints of relevance in gynecologic cancer clinical trials. **2023**, 33, 323-332	0
11	Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions. **2023**, 33, 431-443	0

10	Overcoming PARP inhibitor resistance in ovarian cancer. **2023**, 33, 364-376	0
9	Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights. 11,	1
8	Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. **2023**, 16,	0
7	Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus. 34,	0
6	The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers. **2023**, 24, 7293	0
5	In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study. jcp-2023-208852	0
4	PARP Inhibitors in Breast and Ovarian Cancer. **2023**, 15, 2357	0
3	Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study. ijgc-2022-004211	0
2	Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database.	0
1	Targeted therapy. **2023**, 205-411	0